Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Companies Commented On
- Athersys Inc.
- Biotie Therapies Corp.
- Cleveland BioLabs
- Forest Laboratories Inc.
- H. Lundbeck A/S
- Intercept Pharmaceuticals Inc.
- Ironwood Pharmaceuticals Inc.
- Kyowa Hakko Kirin Co. Ltd.
- MAST Therapeutics Inc.
- Medigene AG
- Merck & Co. Inc.
- NovaBay Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
- Sucampo Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB S.A.
Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.
Seven Biotech Options that Buck Tradition: Christian Glennie (6/6/13) Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside in companies still small enough to double, triple and quadruple in value down the line. In this interview with The Life Sciences Report, Edison Biotechnology Analyst Christian Glennie applies his valuation skills to seven innovative biotech and specialty pharma companies and discusses the share-moving catalysts that investors need to know about now.
"A $2.8M research grant enables ATHX's MultiStem to enter a third phase 2 trial to evaluate the safety and therapeutic impact of its allogeneic adult stem cells." (8/9/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >